natgillin/translations-raw huggingface dataset:
one or more high saturated vegetable butters, wherein the one or more high saturated vegetable butters are selected from vegetable butters having greater than 60 wt % saturated fatty acids based on the total fatty acids of the high saturated vegetable butter, wherein the total amount of high saturated vegetable butters is 10 to 45 wt. % based on the first vegetable butter composition, and one or more low saturated vegetable butters, wherein the one or more low saturated vegetable butters are selected from vegetable butters having less than 60 wt % saturated fatty acids based on the total fatty acids of the low saturated vegetable butter, wherein the total amount of low saturated vegetable butters is 55 to 80 wt. % based on the first vegetable butter composition. 
(c) tekući kozmetički proizvod, pri čemu je tvrdi biljmi maslac visoko zasićeni biljni maslac koji ima više od 60 mas.% zasićenih masnih kiselina temelju ukupnog sadržaja masnih kiselina visoko zasićenog biljnog maslaca, pri čemu je mekani biljni maslac nisko zasićeni biljni maslac koji ima manje od 60 mas.% zasićenih masnih kiselina temelju ukupnog sadržaja masnih kiselina nisko zasićenog biljnog maslaca, i pri čemu "kruti" znači da kozmetički pripravak može uglavnom zadržavati svoj fizički oblik kada nije podržan vanjskim sredstvima, te pri čemu kruti kozmetički pripravak je krut na sobnoj temperaturi i ostaje uglavnom krut na temperaturi do 30?C.
The aqueous formulation for use of claim 18 wherein said pharmaceutical composition further comprises excipients selected from the group consisting of zinc, m-cresol, glycerol, polysorbate 20 and sodium. 
Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 6 do 9, naznačen time da pripravak nadalje sadrži ekscipijente odabrane iz skupine koju čine cink, m-krezol, glicerol, polisorbat 20 i natrij.
or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, wherein: 
Spoj s formulom (I): [image] ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer, naznačen time da: X je C=O ili CH2;
Because in the conventional manufacture of veneers, for technological reasons, such narrow strips of veneer cannot be glued, said aesthetics in veneer can only be achieved by means of the process according to the invention. Modification 
Budući da u konvencionalnoj proizvodnji furnira, iz tehnoloških razloga, takve uske trake furnira ne mogu biti zalijepljene, navedeni estetski izgled furnira može se dobiti samo pomoću postupka koji je u skladu s ovim izumom.
The thieno[3,2-d]pyrimidine derivative or its pharmaceutically acceptable salt of embodiment 1, wherein W is NH. 
2. - Derivat tieno[3,2-dlpirimidina u skladu s patentnim zahtjevom 1, pri čemu W je NH ili njegova farmaceutski prihvatljiva sol.
Each of the two branches of the delivery pipe may be provided with a Venturi suction arrangement. The pumping system may comprise one or more propeller pumps. 
Sustav sukladno patentnom zahtjevu 9, naznačeno time da još svaka od dvije grane cijevi za isporuku ima Venturi usisni sklop (17a, 17b).
Pharmaceutical compositions according to claims 11 to 15 for use in the treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases. Pharmaceutical compositions for use according to claim 16, characterized in that said tumor diseases include malignant neoplasias and metastasis. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 14 do 16, naznačen time što je namijenjen upotrebi u liječenju prekanceroznih lezija, displazija, metaplazija i tumorskih bolesti, što može uključivati zloćudne novotvorine 1 metastaze.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound fluopyram. 
CH naznačen time da je R; difluorometil ili trifluorometil, a X kloro, fluoro, ili bromo; i (B) spoj fludioksonil.
A compound for use according to claim 1, wherein the compound of formula I has the formula IA wherein R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkylaryl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R4 signifies hydrogen, alkyl or -alkylaryl group; X signifies CH2, oxygen atom or sulphur atom; and n is 1, 2 or 3, with the proviso that when n is 1, X is not CH2. 
Spoj za upotrebu prema zahtjevu 1, naznačen time što spoj s formulom I ima formulu IA oi IA naznačen time što Ri, R> i Rs su isti ili različiti i označavaju vodik, halogene, alkil, alkilaril, alkiloksi, hidroksi, nitro, amino, alkilkarbonilamino, alkilamino ili dialkilamino skupinu; R, označava vodik, alkil ili -alkilaril skupinu; X označava CH,, kisikov atom ili sumporov atom; i n je 1, 2 ili 3, pod uvjetom da kada n je 1, X nije CHx.
The cream produced by the process of the present invention contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, in a cream base comprising a preservative, an acid, a co-solvent, an emulsifier and a waxy material along with water, preferably purified water. 
Postupak za proizvodnju kreme s fusidinskom kiselinom prema patentnom zahtjevu 1, naznačen time, da navedena baza kreme sadrži konzervans, kiselinu, ko-otapalo, emulgator te voštanu tvar, zajedno s vodom, prvenstveno pročišćenom vodom.
detecting the formation of the immunological complex, particularly such that presence or absence of the immunological complex correlates with presence or absence of amyloid protein; and correlating the presence or absence of the immunological complex with the presence or absence of amyloid protein in the sample. 
(c) detektiranja formiranja imunološkog kompleksa, za oba oka, tako da prisutnost ili odsutnost imunološkog kompleksa korelira s prisutnošću ili odsutnošću amiloidnog proteina; i (d) koreliranja prisutnosti ili odsutnosti imunološkog kompleksa s prisutnošću ili odsutnošću amiloidnog proteina u uzorku.
the proline at position 5 of the BC loop (SEQ ID NO: 34) is substituted with an amino acid selected from the group consisting of A, C, D, E, I, K, L, M, N, Q, R, S, T, V, and Y; 
(iii) - prolin na položaju 5 u petlji BC (SEQ ID NO: 34) je zamijenjen aminokiselinom koju se bira iz skupine kojučine A,C,D,E,LK,L,M,N, Q,R, S, T, Vi Y;
The composition of claim 13, wherein the thyroid stimulating drug is selected from the group consisting of levothyroxine, levothyroxine sodium, liothyronine sodium, liotrix, thyroglobulin, thyroid, thyroxine, triiodothyronine, levoxyl, synthroid, levo-T, unithroid, levothroid, levoxine, levolet, novothyrox, triostat, cytomel and thyrolar. 
Pripravak koji sadrži (a) lijek, sredstvo, medikament ili hormon izabran iz skupine koju čine levotiroksin, levotiroksin natrij, liotironin natrij, liotriks, tiroksin i trijodtironin i (b) sniženi folat, gdje sniženi folat jest 6(S)-5-metiltetrahidrofolat.
A process according to any one of claims 17 to 19, wherein the compound according to formula (3) is produced in a ratio of diasteromers (3-a) to (3-b) of at least 60: 40, preferably of at least 70: 30, more preferably of at least 80: 20, yet more preferably of at least 90: 10, most preferably of at least 99: 1. 
Postupak prema bilo kojem od zahtjeva 17 do 19, naznačen time, da se proizvodi spoj prema formuli (3) u omjeru sljedećih dijastereomera (3-a) prema (3-b): od najmanje 60: 40, poželjno najmanje 70: 30, još poželjnije najmanje 80: 20, još bolje od najmanje 90: 10, te najbolje od najmanje 99: 1.
delivering an unsaturated solution of the substance to be crystallized into a fluidized bed dryer under conditions of applying a vacuum and maintaining a temperature range, in order to dry the solution of a substance to be crystallized to thereby obtain a supersaturated solution, in which crystallization takes place, 
dostavljanja nezasićene otopine supstance koja treba kristalizirati u sušač fluidiziranog sloja pod uvjetima primjene vakuuma i održavanja temperaturnog opsega, kako bi se otopina supstance koja treba kristalizirati osušila i time dobila prezasićena otopina u kojoj dolazi do kristalizacije, pri čemu se nezasićena otopina pumpa kroz dovodne cijevi, kontrolira mjeračem protoka, zagrijava izmjenjivačem topline i konačno ubrizgava u vakuumsku posudu pomoću mlaznice za raspršivanje,
a heavy chain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:88, or/and 
(i) obuhvaća jaki lanac koji ima najmanje 90% identiteta sekvence prema aminokiselinskoj sekvenci SEQ ID NO:58;
The fractions containing IL-2 were collected and pooled. 
Frakcije koje su sadržavale IL-2 su sakupljene i združene.
Thus, also the so created space 9 is filled with the liquid synthetic resin still being supplied, and it fulfils the function of runner channel improving the throughflow of the liquid resin. 
Stoga se također tako dobiven prostor 9 ispuni s tekućom sintetičkom smolom koju se još uvijek dovodi, i on ispunjava funkciju protočnog kanala koji poboljšava protok tekuće smole.
Dosage form according to any of the preceding embodiments, wherein the application fluid is selected from the group comprising water and an aqueous saline solution, preferably an aqueous NaCl solution, more preferably an aqueous 0.9% (weight/volume) NaCl solution. 
Oblik doziranja prema zahtjevu 1 ili 2, naznačen time da je tekućina za primjenu odabrana iz skupine koja sadrži vodu i vodenu fiziološku otopinu, poželjno vodenu otopinu NaCl, poželjnije 0.9% (masa/volumen) vodenu otopinu NaCI.
In a preferred embodiment, the flavonoid compound comprises at least one carbonyl group, and more preferably those selected from quercitrin, taxifolin, galangin, diosmetin, chrysin or derivatives thereof. 
Biokompatibilni usadak u skladu s patentnim zahtjevom 1, naznačen time što flavonoidni spoj sadrži najmanje jednu karbonilnu skupinu, te što se flavonoid bira između kvercitrina, taksifolina, galangina, diosmetina, krizina ili njegovih derivata.
in which the cancer is an ovarian tumor, a breast cancer, a melanoma, or a mammary carcinoma. The method as claimed in claim 1 wherein said monitoring of said disease comprises determining regression, course or onset of said disease in a sample from a patient who has said disease or is suspected of falling ill with said disease. 
Postupak prema bilo kojem od patentnih zahtjeva 6 do 9 naznačen time što navedeno praćenje navedene bolesti kancera sadrži određivanje regresije, toka ili početka navedene bolesti u uzorku od pacijenta koji ima navedenu bolest ili za koga se sumnja da se razboljeva od navedene bolesti.
A previously assembled cup 12 is then drawn by suction into the shell until the annular periphery of its upper shoulder 32 seats against the inner wall of the shell at the melted area along the contact path 3, see also Figure 7 . 
Prethodno složena čaša 12 se tada uvuče usisavanjem u ljusku sve dok prstenasti obod njezinog gornjeg izbočenja 32 ne nasjedne na ljusku na rastopljenoj traci duž odgovarajuće staze za kontakte 3, vidi također sliku 7.
The outside diameter φe, on the other hand, is chosen according to the stiffness, to the hardness and to the resistance of the material used to produce the core 1 and according to the overall weight of the roll which is wound on the core 1. 
S druge se strane, vanjski promjer (0, odabire tako da bude sukladan sa čvrstoćom, tvrdoćom i otpornošću materijala za izradu jezgre 1, kao i da odgovara ukupnoj težini svitka koji se namata na jezgru 1.
A vaccine composition comprising: a compound PBS-57 of formula: and 
Pripravak cjepiva koji sadrži: a) spoj PBS-57 s formulom:
wherein R5 and n have any of the meanings defined hereinbefore except that any functional group is protected if necessary, and wherein the reaction is conveniently performed in the presence of a suitable acid, and whereafter any protecting group that is present is removed by conventional means. 
Formulom IX: u kojoj R* i n imaju značenja u skladu sa ranije navedenom definicijom, samo što je bilo koja od funkcionalnih skupina po potrebi zaštićena, i pri čemu se reakcija poželjno provodi u prisutnosti odgovarajuće prikladne kiseline, nakon čega se prisutna zaštitna skupina uklanja konvencionalnim postupcima.
further comprising a heterologous polypeptide fused thereto. 
dodatno sadrži heterologni polipeptid fuzioniran s njim.
A compound of formula (I) a stereo-isomeric form, a pharmaceutically acceptable salt, solvate or polymorph thereof comprising a mono- or di-substituted indole group; said compound is selected from the group wherein: 
(I) 5 njegov stereoizomerni oblik, farmaceutski prihvatljiva sol, solvat ili polimorf koji sadrže mono- ili di-supstituiranu indolnu skupinu; navedeni spoj je odabran iz skupine gdje:
wherein: n, D, E, G, R1, R2, R4 and R5 are as defined in claim 1; Ra is selected from the group consisting of alkyl and -OR6; and 
pri čemu: n, D, E, G, R1, R2, R4 i R5 su kao što je definirano u patentnom zahtjevu 1; Ra je odabran iz skupine koju čine alkil i -OR6; i
represents —C(RC)(RD)—, m represents an integer of 1 to 3, 
X? predstavlja -C(R"X(R")-, m predstavlja cijeli broj od 1 do 3,
the carrier being at least one selected from the group consisting of calcium montmorillonite, attapulgite, pumice, perlite, diatomaceous earth, vermiculite, talc and clay. 
nadalje sadrži nosač, - > nosač je barem jedan nosač koji je odabran iz skupine koju čine kalcijev montmorilonit, atapulgit, plovučac, perlit, dijatomejska zemlja, vermikulit, talk 1 glina.
According to any of the foregoing, the actuator may be adapted to delay movement of the container needle from the storage state to the delivery state after an input is received. 
Ubrizgač prema bilo kojem od prethodnih zahtjeva, naznačen time, što je pokretač (456) prilagođen da odgodi kretanje igle spremnika (550, 702, 772) 1z pasivnog stanja u stanje za isporuku nakon primanja unosa.
The organic layer is isolated using the Isolute™ phase separator cartridge and evaporated. 
Organski sloj se izolira pomoću umetka Isolute'" za rastavljanje faza i ispari.
A hand held medicine dosing and dispensing device according to Claim 2 wherein the ejection mechanism is only operable to disengage the latch members and allow removal of the cassette from the housing when the storage chamber of the cassette is empty. 
Ručni uređaj za doziranje 1 izdavanje lijeka prema zahtjevu 2 naznačen time da mehanizam za izbacivanje radi samo tako da oslobađa elemente zasuna i omogućava uklanjanje kasete iz kućišta kada je prazna komora za pohranjivanje kasete.
A process for the purification of compound of formula I, namely Perindopril, comprising steps of: 
Postupak pročišćavanja spoja formule I, odnosno perindoprila COOH
A compound selected from the group consisting of: A compound which is 
Spoj, naznačen time što ga se bira iz skupine koju čine:
The method according to claim 1, wherein the patient has at least one foreseen occurrence of ischemia and/or reperfusion injury, preferably after organ transplantation. 
Upotreba u skladu s patentnim zahtjevom 14, naznačena time što do očekivane pojave ishemije i reperfuzijske ozljede dolazi nakon presađivanja organa. Fiziološka prije
The food processing apparatus of claim 5, wherein at least a first of the plurality of electromagnets at least partially vertically overlaps at least a second of the plurality of electromagnets. 
Uređaj za obradu hrane iz zahtjeva 12, pri čemu barem prvi od više elektromagneta (44C) barem djelomice vertikalno preklapa drugi od više elektromagneta (44C).
A process according to claim 2, which is performed in an aprotic solvent or mixture of solvents comprising dichloromethane, toluene, or a mixture of dichloromethane and toluene. A process for manufacturing the compound of formula I-3 
Postupak prema jednom od zahtjeva 2 do 4, naznačen time, da se izvodi u aprotonskom otapalu ili u smjesi otapala koja se sastoji od diklorometana, toluena, ili od mješavine diklorometana i toluena.
The outer part 10 and 12 are made of a metal material and the inner parts 14 and 16 are made of a plastic material. 
Vanjski dio 10 i vanjski dio 12 su načinjeni od metalnog materijala, a unutarnji dijelovi 14 i 16 su načinjeni od plastičnog materijala.
a first sleeve (S 1) made of a foldable sheet material wrapped over a first pair of opposite frame-members (H 1, H 3); and 
(b) prvi omotač (Su) izrađen od složive folije koja je obavijena oko prvog para nasuprotnih okvirnih elemenata (H,, Hs)i
A method for improving motor performance in a mammal suffering from a synucleinopathy, comprising administration to the mammal of an effective amount of the compound of claim 1 . 
Uporaba spoja prema zahtjevu 1 naznačena time da je za proizvodnju lijeka za uporabu kod poboljšanja motoričkih osobina kod sisavca koji pati od sinukleinopatije.
The soft chewable veterinary composition of claim 1, wherein the composition comprises a solvent and the solvent is a liquid polyethylene glycol or a caprylic/capric triglyceride, or a combination thereof. 
Mekani veterinarski pripravak za žvakanje u skladu sa zahtjevom 6, naznačen time, da otapalo je tekući polietilenglikol ili kaprilični/kaprički triglicerid, ili njihova kombinacija.
converting the compound of Formula XXXIII to a compound of Formula XXXIV; and 
Formula XXXI konverziju spoja Formule XXXIII u spoj Formule XXXTV, i
Progesterone according to any one of the preceding claims, wherein the progesterone is administered from about 0 hours to about 1 hour post injury. 
Progesteron u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se progesteron primijenjuje otprilike 0 sati do otprilike 1 sat nakon ozljede.
Embodiment 16 The method of any of the foregoing Embodiments, wherein less than about 8% of the precipitate particles have a particle size of less than 10 um. 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što manje od 8 % čestica taloga ima veličinu čestica manju od 10 um.
As already mentioned above, in the process according to the invention, the board-like, plane pieces of wood are glued with one another by means of an adhesive, preferably holohedrally. 
Kao što je već bilo gore navedeno, u postupku koji je u skladu s ovim izumom, ravni komadi od drva koji imaju oblik ploče se lijepe jedan s drugim pomoću ljepila, po cijeloj površini.
By modification of the surface by adsorption of a chemical constituent, it is possible to lower the surface energy of the first phase so that the sum of the surface energy and the bulk energy becomes lower than the surface energy and the bulk energy for the second phase, and thereby “reverse” the stability order of the first and second phase. 
Modifikacijom površine adsorpcijom kemijskih konstituenata je moguće smanjiti energiju površine prve faze tako da je suma energije površine i ukupne energije cestica postaje niža od sume energije površine i ukupne energije čestica druge faze i time se "promijeni" redoslijed stabilnosti prve 1 druge faze.
Anticholinergic agents such as glycopyrrolate prevent the effects resulting from passage of impulses through the parasympathetic nerves. 
Antikolinergički agensi, kao što je glikopirolat, sprječavaju učinke nastale prolazom impulsa kroz parasimpatičke živce.
causing the biomasses to pass through a first mechanical size reduction device (1) formed by a knife mill or a hammer mill to enable the biomasses to be reduced to particles; 
-a) izazivanje biomasa da prođu kroz prvi uređaj za mehaničku redukciju veličine (1) koji je formiran pomoću mlina sa nožem ili mlina sa čekićem da bi se omogućilo da biomase budu reducirane do čestica.
On the 6th day after observing no difficulties, her physician removes the BTDS 10 and replaces it with BTDS 20 for 3 days while decreasing her methadone by another 25%. 
Na šesti dan nakon što se utvrdi da ne dolazi do komplikacija, njen liječnik uklanja TSB 10 i zamjenjuje ga s TSB 20 kroz tri dana dok u isto vrijeme snizuje metadon za dodatnih 25%.
FIELD OF THE INVENTION The present invention relates to a sheath device suitable for an endoscopic device, such as a catheter or cystoscope, which, said sheath when mounted onto any optical device, allows for the surgeon to examine or manipulate within an orifice or through a incision, whilst easily manipulating the endoscopic device. 
Područje izuma Predmetni izum se odnosi na uređaj za omatanje koji je prikladan za neki endoskopski uređaj, takav kao što je kateter ili cistoskop, koji navedeni uređaj za omatanje, kada se montira na bilo koji optički uređaj, omogućava kirurgu da pregledava ili da manipulira u otvoru ili kroz rez, pri čemu lagano rukuje s endoskopskim uređajem.
A process as claimed in one or more of the claims 2, 3 and 5 to 12 further comprising the step of recycling the potentially remaining amount of unreacted compounds of the formulae VII and VIII in the reaction mixture by alkaline hydrolysis with aqueous bases in form of the respective 2-(2-hydroxy-5-nitrophenyl)-1-aryl-ethanone of formula IV or the corresponding sodium or potassium salt of the formula V wherein, in the compounds of the formulae IV and V R2 is as defined in formula I. 
13. Postupak u skladu s jedim ili više patentnih zahtjeva 2, 3 i 5 do 12, naznačen time što dodatno uključuje korak recikliranja potencijalno preostale količine neizreagiranih spojeva formula VII i VIII u reakcijskoj smjesi alkalnom hidrolizom vodenom otopinom baza u obliku odgovarajućeg 2-(2-hidroksi-5-nitrofenil)-1-ariletanona formule IV
said detectable moiety is a fluorescent dye, an enzyme, a substrate, a bioluminescent material, a radioactive material, or a chemiluminescent material, or 
odvojivog dijela odabranog između fluorescentne boje, enzima, supstrata, bioluminescentnog materijala, radioaktivnog materijala, ili kemiluminescentnog materijala, ili
TES-Cl was charged to the flask. 
TES-CI je bilo stavljeno u tikvicu.
A process according to any preceding claim, wherein the coarse and microfine excipients are carbohydrates, preferably wherein the coarse excipient is coarse lactose monohydrate, and/or wherein the microfine excipient is microfine lactose monohydrate. 
Postupak u skladu s bilo kojim prethodnim patentnimzahtjevom, pri čemu su grubi i mikrofini_ ekscipijensi ugljikohidrati, poželjno pri čemu je grubi ekscipijens gruba laktoza monohidrat, i/ili pri čemu je mikrofini ekscipijens mikrofina laktoza monohidrat.
35 ml of purified water was used as the granulating solution to prepare granules of the above blend till the mass of required consistency was obtained. 
35 ml pročišćene vode rabljeno je kao otopina za granuliranje da bi se dobile granule gornje mješavine dok se ne bi dobila masa tražene konzistencije.
The isolated fusion protein of claim 7 or claim 8, wherein the fusion protein has a terminal half-life that is at least two-fold longer compared to the biologically active protein not linked to the XTEN. 
Izolirani fuzijski protein prema zahtjevu 7 ili zahtjevu 8, naznačen time, da fuzijski protein ima terminalni poluživot koji je najmanje dva puta dulji u usporedbi s biološki aktivnim proteinom koji nije vezan na XTEN.
A maleate salt of 4-((4-fluoro-2-methyl-1 H -indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline, in the crystalline form Form B, according to claim 5 wherein said salt has an X-ray powder diffraction pattern substantially the same as the X-ray powder diffraction pattern shown in Figure 8. 
Maleatna sol 44((4-fluoro-2-metil-1H-indol-5-il)oksi)-6-metoksi-7-(3-(pirolidin-1-il)propoksi)kinazolina, u kristalnoj Formi B, prema zahtjevu 5, naznačena time, da navedena sol ima uzorak difrakcije X-zraka na puderu koji je podjednak kao i uzorak difrakcije X-zraka na puderu koji je prikazan slici 8.